Table 2

Distribution of ApoE polymorphism among gastric cancer cases and controls
Cases ‡ Controls^ All cases Intestinal (n=79) Diffuse (n=57)
n (%) n (%) OR (95% CI) OR (95% CI) OR (95% CI)
ε3/ε3 109 (71.71) 253 (62.94) 1* 1* 1*
ε3/ε2 15 (9.87) 63 (15.67) 0.43 (0.21 -0.91) 0.34 (0.13 – 0.92) 0.57 (0.23 – 1.40)
ε3/ε4 27 (17.76) 75 (18.66) 0.70 (0.37 - 1.30) 0.75 (0.35 – 1.60) 0.64 (0.27 – 1.47)
ε2/ε2 0 (0.00) 5 (1.24) NC NC NC
ε2/ε4 1 (0.66) 5 (1.24) 1.25 (0.10 - 15.10) 2.54 (0.21 – 31.17) NC
ε4/ε4 0 (0.00) 1 (0.25) NC NC NC
ε3/ε2 or ε2/ε2 15 (12.10) 68 (21.18) 0.40 (0.19 - 0.84) 0.31 (0.11 – 0.83) 0.53 (0.21 – 1.30)
ε3/ε4 or ε4/ε4 27 (19.85) 76 (23.10) 0.68 (0.36 - 1.26) 0.71 (0.34 – 1.53) 0.62 (0.27 – 1.43)

‡ Apolipoprotein genotype was measured in 152 cases.

^ Apolipoprotein genotype was measured in 402 controls.

† OR adjusted by age, gender, alcohol consumption (as continuous variable), packyears of smoking, grilled meat consumption and family history of gastric cancer.

* Reference category.

NC: not calculable due to few many values.

De Feo et al.

De Feo et al. BMC Cancer 2012 12:494   doi:10.1186/1471-2407-12-494

Open Data